Drugs / Aclidinium Bromide/Formoterol Fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01437397 | Sep 2011 → Feb 2013 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aclidinium Bromide/Formoterol Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01437397 ↗ |
| Known as | AB/FF | “investigating the efficacy of aclidinium bromide/formoterol fumarate (AB/FF) fixed-dose combination versus monotherapy or placebo” PMID 31827323 ↗ Dec 2019 |
| Route | Inhaled | “Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day” NCT01437397 ↗ |